Abbott's Healthy Food Program Significantly Improves Health of Diabetes Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2026
0mins
Source: PRnewswire
- Significant Improvements: In a six-month study, 284 adults with type 2 diabetes participating in Abbott's Healthy Food Rx program, combined with community health worker coaching, showed major enhancements in diet, physical activity, and self-management, demonstrating the effectiveness of health interventions.
- Healthy Food Delivery: Participants received bi-weekly family-sized healthy food boxes containing staples, proteins, fruits, and vegetables, along with access to online cooking classes, facilitating positive dietary changes and improving overall health outcomes.
- Role of Community Support: The culturally responsive coaching provided by community health workers not only fostered trust among participants but also helped them manage diabetes more effectively through regular follow-ups and goal-setting, highlighting the significance of community-centered approaches in chronic disease management.
- Long-term Impact Potential: Abbott's Healthy Food Rx program has reached 2,100 participants, with findings indicating that the combination of healthy food access and supportive coaching can effectively lower A1C levels and enhance diet quality, providing a strategic foundation for future health interventions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 88.500
Low
136.00
Averages
148.11
High
169.00
Current: 88.500
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Citi Reiterates Buy Rating on Abbott Laboratories Amid Valuation Insights
- Undervalued Market Position: Citi's analysis suggests that Abbott's individual business segments may be worth more than the current market valuation, estimating a share price range of $99 to $104 compared to the current price of about $89, indicating significant upside potential.
- Product Pipeline Support: Analysts noted that easing market headwinds and the introduction of new products could help Abbott's stock reverse recent pressures, thereby boosting investor confidence and driving price recovery.
- BofA Price Target Adjustment: Although BofA lowered its price target for Abbott from $120 to $102, it maintained a Buy rating, reflecting a cautious outlook on the future utilization trends in the medtech sector, indicating a complex market perspective.
- Challenges in Medtech Sector: Analysts anticipate that inflation will pose additional challenges to margin expansion in 2027, leading to downward adjustments in valuations for several large-cap medtech companies, highlighting the need for Abbott to remain competitive in a challenging environment.
See More
Abbott Declares 410th Consecutive Dividend Payment
- Abbott's Dividend Milestone: Abbott's board declared a quarterly cash dividend of 63 cents per share, marking the 410th consecutive dividend since 1924, showcasing the company's strong financial stability and commitment to shareholder returns.
- Consistent Dividend Growth: Abbott has increased its dividend payout for 54 consecutive years, making it a member of the S&P 500 Dividend Aristocrats Index, which underscores its long-term strategy in shareholder returns and market trust.
- HEICO's Dividend Increase: HEICO announced a semiannual cash dividend of $0.13 per share, an 8% increase from the previous $0.12, reflecting the company's strong performance in profitability and cash flow management.
- Graco's Quarterly Dividend: Graco's board declared a regular quarterly dividend of 29.5 cents per share, payable on August 5, 2026, further solidifying its stability and attractiveness in the market.
See More
AbbVie, Chevron, and Enterprise Products' Dividend Prospects
- AbbVie's Dividend King Status: AbbVie has increased its dividend for 54 consecutive years, boasting a dividend yield exceeding 3%, with seven of its twelve blockbuster drugs generating over $2 billion annually, indicating strong growth potential that is likely to drive stock price appreciation.
- Chevron's Stable Returns: Chevron has raised its dividend for 39 years, currently yielding 3.8%, and can sustain dividends and capital expenditures even if oil prices fall below $50 per barrel, showcasing robust financial resilience and attractiveness to investors.
- Enterprise Products' High Yield: Enterprise Products Partners offers a distribution yield of 5.8% and has increased its distribution for 27 consecutive years, with a strong balance sheet and 90% of long-term contracts insulated from inflation, positioning it favorably in the energy market.
- Market Volatility and Investment Opportunities: While the likelihood of rate cuts remains low due to rising inflation and a strong job market, this dynamic makes stable income investments more appealing, with high-dividend stocks like AbbVie, Chevron, and Enterprise Products becoming top picks for investors.
See More
Top High-Yield Dividend Stocks: AbbVie, Chevron, Enterprise
- AbbVie's Strong Growth: AbbVie markets 12 blockbuster drugs, with 7 generating over $2 billion in annual sales, and boasts a 54-year streak of dividend increases, currently yielding 3%, positioning it strongly in the pharmaceutical sector.
- Chevron's Stable Returns: Chevron has increased its dividend for 39 consecutive years, with a current yield of 3.8%, and has repurchased shares in 18 of the last 22 years, demonstrating a strong commitment to shareholder returns, with expected annual EPS growth of over 10%.
- High Yield from Enterprise Products: Enterprise Products Partners offers a distribution yield of 5.8% and has increased distributions for 27 consecutive years, supported by a strong balance sheet and high credit rating, indicating continued growth potential.
- Market Environment Impact: With rising inflation and a strong job market, increased market volatility may occur, yet high-yield stocks like AbbVie, Chevron, and Enterprise Products are likely to attract income-seeking investors, potentially driving their stock prices higher.
See More
Abbott Laboratories Releases New Diabetes Data
- Rising Hospitalization Rates: Abbott Laboratories presented new data at the American Diabetes Association's 86th Scientific Sessions indicating a significant increase in diabetic ketoacidosis (DKA)-related hospitalizations across all age groups, highlighting the critical need for early risk recognition and enhancing diabetes management strategies.
- CE Mark for New Technology: On May 27, 2026, Abbott announced that its dual glucose-ketone sensing technology, branded as Libre Duo and Libre Duo 10 Day, received CE Mark approval, enabling continuous monitoring of glucose and ketone levels every minute, which aims to provide real-time health insights and reduce the risk of DKA emergencies.
- Updated Cancer Screening Guidelines: On the same day, Abbott revealed that the American Cancer Society updated its colorectal cancer screening guidelines, reaffirming Cologuard and Cologuard Plus as preferred non-invasive screening options for adults aged 45 and older at average risk, thereby strengthening Abbott's position in the cancer screening market.
- Investment Potential Analysis: While Abbott is recognized as a promising investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, reflecting the market's shifting focus and dynamics across different investment sectors.
See More
Boston Scientific Stock Price Decline Analysis
- Poor Stock Performance: Boston Scientific (BSX) shares have fallen over 50% year-to-date, reflecting market disappointment with its growth expectations, particularly as management has repeatedly lowered guidance, undermining investor confidence.
- Guidance Downgrade: The management has revised its 2026 organic revenue growth forecast down to between 6.5% and 8%, and has indicated flat revenue growth for Q2 and Q3, raising concerns about the company's long-term investment appeal amid declining procedure usage.
- Analyst Optimism: Despite the bearish market sentiment, 27 out of 31 analysts still rate the stock as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, which reflects analysts' confidence in the company's recovery potential.
- Valuation Challenges: Boston Scientific currently trades at a mid-teen forward valuation, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which appears challenging in the current market environment.
See More
Citi Reiterates Buy Rating on Abbott Laboratories Amid Valuation Insights
- Undervalued Market Position: Citi's analysis suggests that Abbott's individual business segments may be worth more than the current market valuation, estimating a share price range of $99 to $104 compared to the current price of about $89, indicating significant upside potential.
- Product Pipeline Support: Analysts noted that easing market headwinds and the introduction of new products could help Abbott's stock reverse recent pressures, thereby boosting investor confidence and driving price recovery.
- BofA Price Target Adjustment: Although BofA lowered its price target for Abbott from $120 to $102, it maintained a Buy rating, reflecting a cautious outlook on the future utilization trends in the medtech sector, indicating a complex market perspective.
- Challenges in Medtech Sector: Analysts anticipate that inflation will pose additional challenges to margin expansion in 2027, leading to downward adjustments in valuations for several large-cap medtech companies, highlighting the need for Abbott to remain competitive in a challenging environment.
See More
Abbott Declares 410th Consecutive Dividend Payment
- Abbott's Dividend Milestone: Abbott's board declared a quarterly cash dividend of 63 cents per share, marking the 410th consecutive dividend since 1924, showcasing the company's strong financial stability and commitment to shareholder returns.
- Consistent Dividend Growth: Abbott has increased its dividend payout for 54 consecutive years, making it a member of the S&P 500 Dividend Aristocrats Index, which underscores its long-term strategy in shareholder returns and market trust.
- HEICO's Dividend Increase: HEICO announced a semiannual cash dividend of $0.13 per share, an 8% increase from the previous $0.12, reflecting the company's strong performance in profitability and cash flow management.
- Graco's Quarterly Dividend: Graco's board declared a regular quarterly dividend of 29.5 cents per share, payable on August 5, 2026, further solidifying its stability and attractiveness in the market.
See More
AbbVie, Chevron, and Enterprise Products' Dividend Prospects
- AbbVie's Dividend King Status: AbbVie has increased its dividend for 54 consecutive years, boasting a dividend yield exceeding 3%, with seven of its twelve blockbuster drugs generating over $2 billion annually, indicating strong growth potential that is likely to drive stock price appreciation.
- Chevron's Stable Returns: Chevron has raised its dividend for 39 years, currently yielding 3.8%, and can sustain dividends and capital expenditures even if oil prices fall below $50 per barrel, showcasing robust financial resilience and attractiveness to investors.
- Enterprise Products' High Yield: Enterprise Products Partners offers a distribution yield of 5.8% and has increased its distribution for 27 consecutive years, with a strong balance sheet and 90% of long-term contracts insulated from inflation, positioning it favorably in the energy market.
- Market Volatility and Investment Opportunities: While the likelihood of rate cuts remains low due to rising inflation and a strong job market, this dynamic makes stable income investments more appealing, with high-dividend stocks like AbbVie, Chevron, and Enterprise Products becoming top picks for investors.
See More
Top High-Yield Dividend Stocks: AbbVie, Chevron, Enterprise
- AbbVie's Strong Growth: AbbVie markets 12 blockbuster drugs, with 7 generating over $2 billion in annual sales, and boasts a 54-year streak of dividend increases, currently yielding 3%, positioning it strongly in the pharmaceutical sector.
- Chevron's Stable Returns: Chevron has increased its dividend for 39 consecutive years, with a current yield of 3.8%, and has repurchased shares in 18 of the last 22 years, demonstrating a strong commitment to shareholder returns, with expected annual EPS growth of over 10%.
- High Yield from Enterprise Products: Enterprise Products Partners offers a distribution yield of 5.8% and has increased distributions for 27 consecutive years, supported by a strong balance sheet and high credit rating, indicating continued growth potential.
- Market Environment Impact: With rising inflation and a strong job market, increased market volatility may occur, yet high-yield stocks like AbbVie, Chevron, and Enterprise Products are likely to attract income-seeking investors, potentially driving their stock prices higher.
See More
Abbott Laboratories Releases New Diabetes Data
- Rising Hospitalization Rates: Abbott Laboratories presented new data at the American Diabetes Association's 86th Scientific Sessions indicating a significant increase in diabetic ketoacidosis (DKA)-related hospitalizations across all age groups, highlighting the critical need for early risk recognition and enhancing diabetes management strategies.
- CE Mark for New Technology: On May 27, 2026, Abbott announced that its dual glucose-ketone sensing technology, branded as Libre Duo and Libre Duo 10 Day, received CE Mark approval, enabling continuous monitoring of glucose and ketone levels every minute, which aims to provide real-time health insights and reduce the risk of DKA emergencies.
- Updated Cancer Screening Guidelines: On the same day, Abbott revealed that the American Cancer Society updated its colorectal cancer screening guidelines, reaffirming Cologuard and Cologuard Plus as preferred non-invasive screening options for adults aged 45 and older at average risk, thereby strengthening Abbott's position in the cancer screening market.
- Investment Potential Analysis: While Abbott is recognized as a promising investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, reflecting the market's shifting focus and dynamics across different investment sectors.
See More
Boston Scientific Stock Price Decline Analysis
- Poor Stock Performance: Boston Scientific (BSX) shares have fallen over 50% year-to-date, reflecting market disappointment with its growth expectations, particularly as management has repeatedly lowered guidance, undermining investor confidence.
- Guidance Downgrade: The management has revised its 2026 organic revenue growth forecast down to between 6.5% and 8%, and has indicated flat revenue growth for Q2 and Q3, raising concerns about the company's long-term investment appeal amid declining procedure usage.
- Analyst Optimism: Despite the bearish market sentiment, 27 out of 31 analysts still rate the stock as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, which reflects analysts' confidence in the company's recovery potential.
- Valuation Challenges: Boston Scientific currently trades at a mid-teen forward valuation, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which appears challenging in the current market environment.
See More
